Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.69 |
| ▸ | PI4KA | P42356 | 3/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.64 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.56 |
| ▸ | AHCY | P23526 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23513431 | 0.91 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL16526337 | 0.90 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12922451 | 0.87 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL25752180 | 0.85 | ADORA2A (0.62) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11222112 | 0.85 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12620928 | 0.84 | ADORA2A (0.77) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL11986907 | 0.83 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL12922453 | 0.82 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL29387721 | 0.82 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL233405 | 0.82 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 576 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828633-B1 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2017-11-28 | — | — | US | claimed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| EP-2694524-B1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | US HEALTH (US) | 2016-05-18 | — | — | EP | claimed |
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| US-9206216-B2 | Modified nucleotides methods and kits | PIERCE BIOTECHNOLOGY, INC. (US) | 2015-12-08 | — | — | US | claimed |
| US-20140051846-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | TheUnited ofAmerica,asrepresentedbythe Secre -tary,Department ofHealthand Human Service (US) | 2014-02-20 | — | — | US | claimed |
| EP-2694524-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2014-02-12 | — | — | EP | claimed |
| EP-2669291-A1 | Modified Nucleotides Methods and Kits | Pierce Biotechnology, Inc. (US) | 2013-12-04 | — | — | EP | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| CN-102894010-A | Composition for promoting photosynthesis of plants | BEIJING ZHONGWEI SHENNONG CHRONIC MEDICAL RES INST CO LTD | 2013-01-30 | — | — | CN | claimed |
| US-20080221314-A1 | Heteromolecular metal-humic (chelate) complexes | TIMAC AGRO ESPANA, S.A. (ES) | 2008-09-11 | — | — | US | claimed |
| US-7303916-B2 | Sustained totipotent culture of selected monocot genera | UNIVERSITY OF SOUTH CAROLINA (US) | 2007-12-04 | — | — | US | claimed |
| US-20050102719-A1 | Sustained totipotent culture of selected monocot genera | UNIVERSITY OF SOUTH CAROLINA (US) | 2005-05-12 | — | — | US | claimed |
| US-6821782-B2 | SELECTING AN EXPLANT OF LIVING TISSUE FROM THE PLANT AND CULTIVATING THE TISSUE ON A PRIMARY MEDIUM TO PRODUCE TOTIPOTENT TISSUE | UNIVERSITY OF SOUTH CAROLINA RESEARCH FOUNDATION | 2004-11-23 | — | — | US | claimed |
| US-20030143744-A1 | Method for the production of cotton somatic embryos | SYNGENTA LIMITED (GB) | 2003-07-31 | — | — | US | claimed |
| EP-1274855-A1 | METHOD FOR THE PRODUCTION OF COTTON SOMATIC EMBRYOS | Syngenta Limited (GB) | 2003-01-15 | — | — | EP | claimed |
| WO-2001068886-A1 | METHOD FOR THE PRODUCTION OF COTTON SOMATIC EMBRYOS | SYNGENTA LIMITED (GB) | 2001-09-20 | — | — | WO | claimed |
| WO-1998007310-A1 | INSECT-RESISTANT TRANSGENIC EGGPLANT AND METHOD OF MAKING | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1998-02-26 | — | — | WO | claimed |
| EP-0681428-B1 | PROCESS FOR REGENERATING THE COCONUT PALM FROM EXPLANTS | ORSTOM (FR) | 1997-10-22 | — | — | EP | claimed |
| EP-0132360-A2 | Plant growth medium | SANDOZ LTD. (CH) | 1985-01-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051846-A1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | NSUN2, RNGTT, RNMT | ADORA2A 548/4885ADORA1 572/4885ADORA2B 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.